To date, the number of days of professional or intermittent glucose sensor wear for studies in insulin-treated type 2 has been varied and is usually less than seven days.7,11,27 Our findings add to the body of evidence for CGM use in type 2 diabetes and recommendations that 14 days of CGM data is effective at providing enough glucose data to enable review of glucose control to target lowering of HbA1c.29, –31. The gene discussed is INS; the disease is type 2 diabetes mellitus.